Changes with health plans can be disruptive to patients with diabetes who face changes in supplies and medications that make it difficult to manage their disease, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
Changes with health plans can be disruptive to patients with diabetes who face changes in supplies and medications that make it difficult to manage their disease, said Jaime A. Davidson, MD, FACP, MACE, professor of medicine, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center.
Transcript
What challenges have your Medicare patients had in ordering diabetes supplies and has it affected their health?
Actually, it’s disruptive. I call the system disruptive. Because every year there are changes. We have an article actually that shows for supplies, especially for glucose sticks and meters, they decided to have a big change and when the patients receive the new meters or the new strips they didn’t know how to use them, they didn’t trust them, they didn’t use them, and actually that was very disruptive and people got out of control.
And the same is true for medications. Every year they change plans. It’s not just Medicare, it’s plans that we need to check on a yearly basis because this plan looks better. And then if one of the patients is taking, for example, one type of insulin, the new plan may not have it. And then they will exchange from a different insulin. And then, there’s a lot of confusion.
So, I call that part of the system disruptive. Economically, they think they save money, but at the end it costs us all more money, because the patients don’t do as well.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More